CaroGen Corporation carogencorp.com

CaroGen provides a platform technology for generating vaccines, which is based on replication-proficient, virus-like vesicles (rVLVs) allowing target antigens to accumulate in high levels in cells, thereby amplifying specific immune responses and creating more potent immune therapies. The company, which has licensed its core technology from Yale University, will focus initially on a treatment for patients with chronic hepatitis B infections.

CaroGen provides a platform technology for generating vaccines, which is based on replication-proficient, virus-like vesicles (rVLVs) allowing target antigens to accumulate in high levels in cells, thereby amplifying specific immune responses and cre...Show all

Company (Alive / Active)

All investors data 2 Investors

• Connecticut Innovations
• Undisclosed Investors

Board Members

Competitors

Patents